Launch Excellence 2020

Blue Latitude Health|18th November 2019

In the past year, the competition in biosimilars and complex generics has complicated the launch landscape. An abundance of discoveries coupled with radically evolving stakeholder needs is also straining the traditional pharmaceutical launch.

In this special pack, we provide a comprehensive outlook of launch excellence. We cover topics ranging from gathering effective insights, to understanding the current landscape, and the importance of pre-launch strategy for improving relationships between the customer and the brand.

The report also features interviews with key players such as organisational transformation expert Philip Atkinson. He shares his unique perspective on the importance of structuring agile organisational change to help pharmaceutical companies adapt and stay competitive.

These articles are complemented by case studies curated by our experienced in-house team.

In this publication, we help you answer the following questions:

  • Are you prepared for a successful launch?

  • How can you use insights to understand customers decision-making behaviour?

  • What are you missing in your CAR-T service launch?

  • How do you stay competitive with a lean pharmaceutical launch?

  • Multi-indication launches - how do you navigate in this space? 

Maximising the commercial potential of the pharmaceutical pipeline

Blue Latitude Health|3rd April 2020

Decisions made early in the drug development process can define the limits of what’s possible for products and portfolios. So, why aren’t commercial teams always involved in these early conversations? In this Q&A we deep dive into early stage strategy, including how to break down these siloes and rethink drug development and clinical trial design.

read more

In-progress treatments for COVID-19: an attempt to simplify things

Manos Mastorakis|27th March 2020

Senior Associate Consultant, Manos Mastorakis, takes a look at a number of COVID-19 drugs that are already registered in clinical trials, providing analysis aiming to simplify the current landscape.

read more

Why I became a multiple myeloma patient advocate

Imogen Coupe|6th March 2020

BLH speaks to MM patient advocate, Peter McCleave, to find out how he has fought to remain positive throughout his treatment journey while simultaneously leading a successful campaign to get more people to sign up to be a blood stem cell donor.

read more